Determining the antiviral properties and mechanism of actions of BOLD-100 against SARS-CoV-2 in 2D and 3D cell culture systems

BOLD-100 is a promising new clinical stage therapeutic, originally developed for the use as a cancer treatment. The mechanism of action for BOLD-100 suggests that this therapeutic might also protect against infections with viruses, including coronaviruses like SARS-COV-19. The purpose of this project is to test the antiviral efficacy of BOLD-100 against SARS·COV-19 in 20 and 30 cell culture models, and then investigate the mechanism of action. These results will help define BOLD-100 as an antiviral treatment and support clinical investigations into BOLD-100 for the treatment of COVID-19.

Amy Short
Faculty Supervisor: 
François Jean
British Columbia
Partner University: